Canada: Competition Bureau Discontinues Pharma Abuse Of Dominance Investigation

Published by the Competition / Antitrust & Foreign Investment Group

On December 20, 2018, the Competition Bureau (Bureau) discontinued its abuse of dominance investigation into certain brand name drug manufacturers (Brands), including Celgene, Pfizer and Sanofi-Aventis, that it had launched in November 2016. The Bureau investigated whether such Brands were making it difficult for generic drug manufacturers (Generics) to get access to samples (known also as Canadian reference products), which Generics require in order to develop bio-equivalent generic versions of brand name drugs. The Bureau expressed concerns about the conduct, but concluded that it had insufficient evidence of anti-competitive effects to bring an application before the Competition Tribunal. The Bureau left open the possibility of enforcement action in the future.


In its position statement, the Bureau explained that its inquiry focused on: (i) alleged restrictions imposed by Brands on their wholesalers or distributors that could prevent them from supplying samples to Generics, and (ii) the manner in which Brands dealt with direct requests from Generics for samples. Additionally, it was alleged that Celgene operated a risk management program (required by Health Canada to control access to drugs that pose health and safety risks) in an unduly restrictive manner that blocked Generics' access to samples, which was not necessary to achieve the purpose of the program.

The Bureau did not find that Celgene's risk management program limited the supply of samples to Generics in an anti-competitive fashion. However, the Bureau appears to have found that Celgene refused to supply samples covered by a risk management program to any Generic, despite concluding that Generics have requested such samples. The Bureau found that Generics were able to procure samples from Celgene through other means. As such, the Bureau was not convinced that Celgene's conduct resulted in a substantial prevention or lessening of competition, a prerequisite for a finding of abuse of dominance.

The Bureau did not find sufficient evidence that the policies of the other Brands inhibited Generics' access to samples and, in fact, found that Generics were able to access samples. Since generic entry was not substantially delayed or prevented, this required element of abuse of dominance was not present again. The message from the Bureau appears to be that if generics did not have alternative sources, the Bureau may well have taken action against Celgene.       

Guidance to Pharmaceutical Companies

In addition to discussing the specific allegations that were the subject of inquiry, the Bureau offered some general guidance to the pharmaceutical industry:

  • In order to abuse one's dominance, one must be dominant in a market. Generally, the Bureau considers a given active ingredient to constitute a product market (i.e., a brand name drug plus any generic versions) and Canada to be the geographic market. As such, the Bureau is likely to conclude that a Brand has 100% market share, and is, therefore, dominant, with respect to brand name drugs where generic entry has not yet occurred.
  • Section 79(5) of the Competition Act states that abuse of dominance does not apply to conduct that is the mere exercise of an intellectual property right, such as a pharmaceutical patent. The Bureau's view is that Brands blocking Generics' access to their samples to stifle the development of generic drugs is more than the mere exercise of an intellectual property right and, thus, could constitute abuse of dominance provided that the other factors are met as well.
  • The Bureau noticed that it is becoming more popular for Brands to limit distribution of their drugs (e.g., only through specialty pharmacies) and cautioned that, to the extent the limitation is implemented to foreclose generic entry, the practice could raise competition issues.


The pharmaceutical industry continues to be an area of focus for the Bureau. For example, we previously reported on the Bureau's discontinued investigation into Alcon for "product hopping" and its white paper on pharmaceutical patent settlements. Moreover, as the Bureau noted, Generics' access to samples is an issue in the U.S. as well. The U.S. Food & Drug Administration has found that risk management programs have been used to block Generics from obtaining samples, and this issue is being addressed by proposed legislative changes. It is common for the Bureau to pick up on issues that have been identified in the U.S., and it appears that that is what happened with this inquiry.

Even though Celgene, Pfizer and Sanofi-Aventis avoided enforcement action, a Bureau inquiry creates risk (legal, financial, reputational and otherwise), not to mention the costs and distraction of dealing with the investigation. Before implementing any policy or practice that could restrict the ability of Generics to bring generic drugs to market, a competition law assessment should be undertaken.

To view the original article click here

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions